Aldeyra Therapeutics Inc. presented an update on its research and development pipeline, highlighting progress across several immune-mediated disease programs. The company's RASP platform is advancing multiple candidates, including reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-248 and ADX-246 for atopic dermatitis, obesity/hypertriglyceridemia, and CNS/neuroinflammatory diseases. ADX-2191, which has received orphan drug designation from the U.S. FDA, is being developed for primary vitreoretinal lymphoma and retinitis pigmentosa. The investigational drug ADX-629 has demonstrated activity in Phase 2 clinical trials for autoimmune diseases such as psoriasis and atopic dermatitis, as well as hepatic inflammation and chronic cough. Statistically significant changes in lipid profiles were observed in multiple clinical trials with ADX-629. As of September 30, 2025, Aldeyra reported $75.3 million in cash, cash equivalents, and marketable securities, which it believes will fund operations into the second half of 2027. You can access the full presentation through the link below.